DarioHealth Corp. (DRIO)
DarioHealth Corp. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $7.75, up 1.04% on the session, giving a market capitalisation of $56.7M. On trailing twelve-month figures it carries a trailing P/E of 11.23, a net margin of 322.8%. Its beta of 1.11 implies it has historically moved more than the broad market.
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DarioHealth Corp. is most often compared with the following Healthcare names: